About Pharming Group
Pharming Group is a publicly listed company based in Leiden (Netherlands) founded in 1988. Recombinant protein-based therapeutics for rare diseases are developed. Pharming Group has completed 2 acquisitions, including Abliva and DNage. Its website pharming.com draws about 17 thousand monthly visits. Pharming Group offers products and services including Joenja. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is PHARMING TECHNOLOGIES.
Company details
Pharming Group was founded in 1988 and is headquartered in Leiden, Netherlands. Focus is placed on the biotechnology sector, where recombinant protein-based therapeutics are developed for rare diseases. Operations include the production of Ruconest, a recombinant human C1 esterase inhibitor used in treating angioedema attacks. Additional therapies encompass enzyme replacement for Pompe disease, leniolisib for APDS, and rhC1INH for pre-eclampsia, acute kidney injury, and COVID-19.
- Headquarters Leiden, Netherlands
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website pharming.com
- Social LinkedIn X
- Legal Name Pharming Group Nv
Products & Services of Pharming Group
Pharming Group offers a comprehensive portfolio of products and services, including Joenja.
Treatment for APDS rare disease through precision medicine.
Funding Insights of Pharming Group
- Total Rounds 7
- Last Round Post-IPO — $139.1M
- Investors Count 6
All 7 funding rounds of Pharming Group with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $139.1M | Post-IPO | – | – | – |
| May 2017 | $100M | Post-IPO | – | – | |
| Dec 2016 | $60.08M | Post-IPO | – | – | – |
| Oct 2013 | $16.29M | Post-IPO | – | – | |
| Sep 2008 | $86,000 | Grant | – | – | |
| Oct 2007 | $99.75M | Post-IPO | – | – | – |
| Jun 1995 | Unspecified | – | – |
6 investors in total: 6 institutional.
Investors in Pharming Group
Pharming Group has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Orbimed and Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Investment opportunities in healthcare are managed by Broadfin Capital. | 2005 | broadfin.com | Melville, United States | |
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Provides alternative investment management services as a SEC-regulated advisory firm. | 1983 | kingdon.com | New York, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Pharming Group
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pharming Group
39 people are tracked at Pharming Group (21 in leadership, 7 in board & advisors, 11 in team).
| Name | Role | Group |
|---|---|---|
Nigel van Kampen | Senior HR Business Partner EU & ROW | Leadership |
Inés Bernal | Chief People Officer And Member Of The Executive Committee | Leadership |
Jeroen Wakkerman | Chief Financial Officer | Leadership |
Sijmen de Vries | Executive Director & CEO | Leadership |
Rosemary van Giezen | Director Global Compensation And Benefits At Pharming Groep | Leadership |
Mireille Sanders | Chief Operations Officer | Leadership |
Anurag Relan | Chief Medical Officer | Leadership |
Dolf Kuijper | Senior Director Finance Operations | Leadership |
Daniel Franks | Sr Regional Medical Director, Middle East, North Africa, Turkey, CEE | Leadership |
Brian Hartline | Senior Medical Director | Leadership |
Wesley Blankenship | Director Medical Science - Immunology And Inflammation | Leadership |
Andrew Baumker | Vice President Head Of Sales US | Leadership |
Mike Hilton | Senior Regional Business Director | Leadership |
Stephen Toor | Chief Commercial Officer | Leadership |
Jonathon Fendelman | Sr. Director, Global Business Development | Leadership |
Alexander Breidenbach | Chief Business Officer | Leadership |
Kenneth Lynard | Chief Financial Officer | Leadership |
Mark Moore | Sr. Regional Director Medical Affairs | Leadership |
Shawn Hayes | Director Of Medical Science | Leadership |
John Whalen | Executive Director, Head Of Market Access Eu/row | Leadership |
19 more people are available in the full profile.
Complete people profiles for Pharming Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Pharming Group
Pharming Group is a publicly listed company on the EURONEXT with ticker symbol PHARM in Netherlands, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 May 2010
- Listed onEuronext: PHARM
- Listed entityPharming Group NV
- Exchange sectorHealth technology
- ISINNL0010391025
- Share price0.85 EUR (+0.24% on the day) · 2026-10-14
- Market capitalisation598,075,176.00 EUR
- Price to earnings78.4
- EPS (diluted, trailing year)0.01 EUR
- Volume (last session)654,137
Financials of Pharming Group
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 333.3M EUR | 2.5M EUR | 28.0M EUR |
| 2024 | 274.8M EUR | -10.9M EUR | 6.8M EUR |
| 2023 | 226.9M EUR | -9.8M EUR | -10.2M EUR |
| 2022 | 195.7M EUR | 13.0M EUR | 12.0M EUR |
| 2021 | 168.2M EUR | 13.5M EUR | 17.0M EUR |
Detailed financial statements for Pharming Group
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pharming Group
Pharming Group has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Abliva and DNage.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drugs are developed to treat multiple neurological disorders. | abliva.com | Lund, Sweden | 2000 | Feb 2025 | •••• | |
Therapies for DNA damage-related ageing diseases are developed. | dnage.nl | Leiden, Netherlands | 2004 | Oct 2006 | •••• |
Complete acquisition details for Pharming Group
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Pharming Group
6 dated milestones of Pharming Group across 37 years, from founding to its latest funding, stage changes and deals.
Web traffic of Pharming Group
The website of Pharming Group (pharming.com) receives about 16.8K visits a month and ranks #1,623,426 among all websites worldwide, #2,188 in Biotechnology and Pharmaceuticals.
- Monthly visits16.8K
▲ 5.7% vs previous month
- Unique visitors6.3K
per month
- Global rank#1,623,426
among all websites
- Category rank#2,188
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.7
- Average visit14 sec
- DevicesDesktop 28% · Mobile 72%
Websites whose visitors overlap most with Pharming Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
haei.org | haei.org | 100% | #1,777,460 | – | |
| jerini.com | 97% | View details | |||
| viropharma.com | 97% | View details | |||
asn-online.org | asn-online.org | 50% | #302,118 | – | |
| fiercepharma.com | 33% | #124,066 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Pharming Group
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pharming Group
Complete news archive for Pharming Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pharming Group
Pharming Group was founded in 1988 and raised its 1st funding round 7 years after it was founded.
Pharming Group is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Annual revenue of Pharming Group is $391.6M as on Dec 31, 2025.
Pharming Group was founded in 1988 and is headquartered in Leiden, Netherlands. Focus is placed on the biotechnology sector, where recombinant protein-based therapeutics are developed for rare diseases. Operations include the production of Ruconest, a recombinant human C1 esterase inhibitor used in treating angioedema attacks. Additional therapies encompass enzyme replacement for Pompe disease, leniolisib for APDS, and rhC1INH for pre-eclampsia, acute kidney injury, and COVID-19.
Pharming Group offers Joenja.
Yes, Pharming Group is publicly traded on EURONEXT under the ticker symbol PHARM.
Pharming Group has 6 investors. Key investors include HHS, Orbimed, Deerfield, Kingdon Capital Management, and Broadfin Capital.
Pharming Group operates through Pharming Technologies.